Deadline: 18-Feb-24
CSL Behring is pleased to announce the Local Empowerment for Advocacy Development Grants Program.
CSL Behring will award LEAD Grants to organizations that submit proposals demonstrating that financial assistance would help them address important local and state advocacy issues and initiatives.
Local patient organizations have already demonstrated significant leadership in tackling complex legislative and regulatory public policy issues. Advocacy can, however, be costly. CSL Behring LEAD Grants will help defray these costs. Moreover, CSL Behring will work with the grant recipients to advance their objectives in order to obtain success.
Examples of advocacy issues for a LEAD Grant:
- Creative advocacy endeavors designed to address a local public policy issue or to positively impact users of plasma-derived, recombinant or other innovative therapies
- The pursuit of standard-of-care or quality-of-care legislation or regulations for plasma-derived therapies, their recombinant alternatives or other innovative therapies
- The pursuit of legislation or regulations that will increase early diagnosis and access for patients to obtain their plasma-derived, recombinant or other innovative therapy
- The creation of a grassroots program to influence local legislation
Funding Information
- CSL Behring Local Empowerment for Advocacy Development (LEAD) Grants are community-based grants of approximately €10,000 in Europe.
Eligibility Criteria
- In order to qualify, a local organisation must be:
- a recognised patient advocacy organisation representing individuals advocating for access to plasma/recombinant therapies and other innovative therapies to treat bleeding disorders, immune disorders, Alpha 1 deficiency, Hereditary Angioedema, or Sickle Cell disease
- a non-profit organisation
- an organisation currently addressing a specific advocacy issue or intending to address such an issue
For more information, visit CSL Behring.
